Friday, October 26, 2018
Practice Management II: Teleneurology: What You Need to Know 10:00 a.m.–11:30 a.m. • CME: 1.5 Credit Program Director: Brad Klein, MD, MBA, FAAN, Willow Grove, PA Patients and health systems are increasingly demanding care through telemedicine. While it has become mainstream in hospitals and health systems, there remain many opportunities for private practicing neurologists to also leverage telemedicine and contribute to patient access, convenience, and continuity of care. This course will provide a structured approach towards the practical incorporation of remote care into a neurology practice. Through case studies and examples, we will cover reimbursement/financial models, implementation, client engagement, insurance, regulations, direct to consumer models, hospital contracting, and medicolegal concerns. Upon completion, participants should be able to identify what remote care paradigms are appropriate for specific types of care and what technical, regulatory, and legal standards are required as well the concerns and limitations for the appropriate practice of remote care in neurology. 10:00 a.m.–10:45 a.m. What You Need to Know About Remote Care Eric Anderson, MD, PhD, Gulport, FL 10:45 a.m.–11:15 a.m. A Step-by-Step Guide to Implementing Teleneurology in a Private-Practice Setting David Evans, MBA, Dallas, TX 11:15 a.m.–11:30 a.m. Questions and Answers Faculty
Multiple Sclerosis Therapy: Overview: Clinical Advances 10:00 a.m.–11:30 a.m. • CME: 1.5 Credits Program Director: Scott Newsome, DO, FAAN, Baltimore, MD It is extremely important for clinicians treating MS to enhance their knowledge base about the changing landscape of the MS disease-modifying therapies (DMTs). Making treatment decisions for an individual MS patient is a daunting task and the individualized patient benefit-risk assessment becomes increasingly difficult as new therapies emerge. Furthermore, if these therapies become available, clinicians need to have a full understanding of their benefit-risk profiles. Faculty will review the efficacy and safety profiles of current and late-stage emerging MS DMTs. It is equally challenging to define what constitutes optimal and suboptimal response to DMTs for an individual patient. Moreover, it is critical for clinicians to be able to recognize short-term clinical and paraclinical factors that may help identify patients at high risk for long-term disability. Faculty will review key considerations in MS clinical practice to address the above challenges in both didactic and case-based formats. Participants should feel more confident in prescribing and monitoring multiple sclerosis (MS) disease-modifying therapies (DMTs) as it relates to their efficacy and safety profiles, and develop a better understanding of key considerations in clinical practice; become familiar with late-stage DMTs that have a strong potential of getting approved for use in MS; and be able to recognize what factors put an MS patient at risk for long-term disability and when to consider switching therapies.
10:00 a.m.–10:50 a.m. The Expanding Armamentarium of Multiple Sclerosis Scott Newsome, DO, FAAN, Baltimore, MD 10:50 a.m.–11:25 a.m. Case-based Considerations in Clinical Practice for Multiple Sclerosis Carrie Michelle Hersh, DO, MSc, Las Vegas, NV 11:25 a.m.–11:30 a.m. Questions and Answers Faculty
8
2018 American Academy of Neurology Fall Conference